While most health tech startups chase AI hype, Neuronostics is quietly building the mathematical foundation for neurological diagnostics. Their BioEP platform isn't just another EEG analysis tool—it's a computational engine designed to make epilepsy diagnosis faster, more accurate, and more accessible.

"They're not building another dashboard—they're building the computational backbone for neurological diagnostics."

The company's technical stack reveals their priorities: Tailwind CSS and Bootstrap for rapid UI development, jQuery for legacy compatibility, and Google Analytics for data-driven iteration. They're building lean—15 people, $3.1M in revenue, focused on product over marketing. Their social presence is minimal but strategic: LinkedIn for B2B credibility, Facebook for broader reach, while their Twitter link points to Firefox—a curious omission that suggests either a placeholder or a deliberate focus on platforms where healthcare decision-makers actually engage.

• Mathematical modeling over AI hype: BioEP uses computational neuroscience, not just deep learning black boxes
• Digital biomarkers: Creating quantifiable metrics for neurological conditions that were previously subjective
• Regulatory-first approach: Lucy Rogers leads regulatory affairs, indicating they're building for FDA/CE approval from day one
• Clinical operations focus: Milaana Mainstone heads clinical ops, showing they're serious about real-world validation